Article Text

Download PDFPDF
Do beta-blockers and inhibitors of the renin–angiotensin aldosterone system improve outcomes in patients with heart failure and left ventricular ejection fraction >40%?

Statistics from


  • Contributors RTL wrote the manuscript. NM, KM, JM and CD reviewed the manuscript and approved for submission.

  • Funding This study was supported by an NIHR Cochrane Incentive Award (16/21/19). RTL was supported by an NIHR Clinical Lectureship (CL-2014-18-007) and subsequently by a UKRI Rutherford Fellowship hosted by Health Data Research UK (MR/S003754/1).

  • Competing interests CD has received sponsorship from Servier, Roche and Novartis to attend cardiology conferences, payment from GE Healthcare to give lectures on heart failure and has served as a paid consultant to Servier and Vifor. RTL has received research grants from Pfizer and has served as an unpaid consultant to GSK.

  • Provenance and peer review Commissioned; internally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.